Our top pick for
Calix, Inc is a software—application business based in the US. Calix shares (CALX) are listed on the NYSE and all prices are listed in US Dollars. Calix employs 763 staff and has a trailing 12-month revenue of around USD$455.4 million.
Since the stock market crash in March caused by coronavirus, Calix's share price has had significant positive movement.
Its last market close was USD$25.52, which is 59.29% up on its pre-crash value of USD$10.39 and 354.90% up on the lowest point reached during the March crash when the shares fell as low as USD$5.61.
If you had bought USD$1,000 worth of Calix shares at the start of February 2020, those shares would have been worth USD$644.04 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$2,795.21.
|Latest market close||USD$25.52|
|52-week range||USD$5.61 - USD$22.69|
|50-day moving average||USD$19.1774|
|200-day moving average||USD$15.6698|
|Wall St. target price||USD$24.2|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.364|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-19)||6.11%|
|1 month (2020-10-26)||0.71%|
|3 months (2020-08-26)||25.28%|
|6 months (2020-05-26)||99.84%|
|1 year (2019-11-26)||223.45%|
|2 years (2018-11-26)||158.30%|
|3 years (2017-11-24)||267.19%|
|5 years (2015-11-25)||241.63%|
Valuing Calix stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Calix's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Calix's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$10.4 million.
The EBITDA is a measure of a Calix's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$455.4 million|
|Gross profit TTM||USD$187.9 million|
|Return on assets TTM||-0.45%|
|Return on equity TTM||-9.16%|
|Market capitalisation||USD$1.3 billion|
TTM: trailing 12 months
There are currently 2.0 million Calix shares held short by investors – that's known as Calix's "short interest". This figure is 17.6% up from 1.7 million last month.
There are a few different ways that this level of interest in shorting Calix shares can be evaluated.
Calix's "short interest ratio" (SIR) is the quantity of Calix shares currently shorted divided by the average quantity of Calix shares traded daily (recently around 863925.32188841). Calix's SIR currently stands at 2.33. In other words for every 100,000 Calix shares traded daily on the market, roughly 2330 shares are currently held short.
However Calix's short interest can also be evaluated against the total number of Calix shares, or, against the total number of tradable Calix shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Calix's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Calix shares in existence, roughly 30 shares are currently held short) or 0.038% of the tradable shares (for every 100,000 tradable Calix shares, roughly 38 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Calix.
Find out more about how you can short Calix stock.
We're not expecting Calix to pay a dividend over the next 12 months.
Over the last 12 months, Calix's shares have ranged in value from as little as $5.61 up to $22.69. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Calix's is 1.5472. This would suggest that Calix's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Calix, Inc., together with its subsidiaries, provides cloud and software platforms, and systems and services required to deliver the unified access network in the United States, the Middle East, Canada, Europe, the Caribbean, and internationally. The company's cloud and software platforms, and systems and services enable communication service providers (CSPs) to provide a range of services, such as basic voice and data, and advanced broadband services. Its premises systems allow CSPs to master the complexity of the smart and connected homes, and offer services to differentiate through the delivery of a subscriber experience. The company offers Calix Cloud, an analytics platform that leverages network data and subscriber behavioral data to deliver analytics and intelligence to communications professionals through role specific dashboards; and Calix Marketing Cloud for CSP marketing teams, as well as Calix Support Cloud for CSP customer support teams. It also provides Experience eXtensible Operating System, a carrier class premises operating system and software platform that supports residential, business, and mobile subscribers; and Access eXtensible Operating System, a software platform built for the specific needs of the access network. The company offers its products through its direct sales force and resellers. Calix, Inc. was founded in 1999 and is headquartered in San Jose, California.
Everything we know about the NewRez IPO, plus information on how to buy in.
Everything we know about the Perella Weinberg IPO, plus information on how to buy in.
Everything we know about the Nanobiotix IPO, plus information on how to buy in.
Everything we know about the Diversey IPO, plus information on how to buy in.
Everything we know about the Certara IPO, plus information on how to buy in.
Everything we know about the Arrival IPO, plus information on how to buy in.
Everything we know about the iSpecimen IPO, plus information on how to buy in.
Everything we know about the IDEX Biometrics ASA IPO, plus information on how to buy in.
Steps to owning and managing MYSZ, with 24-hour and historical pricing before you buy.
Steps to owning and managing MG, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.